Concordantly, the simultaneous targeting of mouse Vegfr2 and DLD1 carcinoma-produced VEGF-A with the antibodies DC101 and bevacizumab, respectively, led to increased vascular expression of Cx3cl1 and reduced extravasation of HPMo to DLD1 xenografts. The gene discussed is KDR; the disease is carcinoma.